Article thumbnail
Location of Repository

Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients

By Rosanna Squitti, Carlo C. Quattrocchi, Gloria Dal Forno, Piero Antuono, David R. Wekstein, Concetta R. Capo, Carlo Salustri and Paolo M. Rossini

Abstract

A dysfunction in copper homeostasis seems to occur in Alzheimer’s disease (AD). We previously evidenced that an excess of non-ceruloplasmin-copper (NCC) correlated with the main functional, anatomical as well as cerebrospinal markers of the disease. Aim of our study was to investigate ceruloplasmin isoforms as potential actors in this AD copper dysfunction. Our data show that AD patients have ceruloplasmin fragments of low molecular weight (<50 kDa) both in their serum and brain, contrary to healthy controls. Ceruloplasmin isoforms of higher molecular weight (115 and 135 kDa in serum and 135 kDa in brain), as well as copper levels in the brain, instead, do not seem to mark a difference between AD and healthy subjects. These data suggest a ceruloplasmin fragmentation in the serum of AD patients. Some clues in this direction have been found also in the AD brain

Topics: Original Research
Publisher: Libertas Academica
OAI identifier: oai:pubmedcentral.nih.gov:2716788
Provided by: PubMed Central

Suggested articles

Citations

  1. (1986). A comparative study of modifi ed Bielschowsky, Bodian and thiofl avin S stains on Alzheimer’s neurofi brillary tangles.
  2. (1997). A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes.
  3. (2005). A subcellular prefractionation protocol for minute amounts of mammalian cell cultures and tissue.
  4. (1993). Age-related changes in human ceruloplasmin. Evidence for oxidative modifi cations.
  5. (2001). Brain donation in normal aging: procedures, motivations, and donor characteristics from the Biologically Resilient Adults
  6. (2006). Cerebrospinal fl uid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer’s disease. Neural Transm, Epub Ahead of print.
  7. (1998). Cerebrospinal fl uid levels of transition metals in patients with Alzheimer’s disease.
  8. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA
  9. (2003). Clinical Investigations standing Committee of the association of Clinical Biochemists. Wilson’s disease: the importance of measuring serum caeruloplasmin non-immunologically.
  10. (2005). Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer’s disease.
  11. (2004). Copper perturbation in 2 monozygotic twins Discordant for degree of cognitive impairment.
  12. (1998). Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer’s disease: a case-control study.
  13. (1998). Copper, iron and zinc in Alzheimer’s disease senile plaques.
  14. (1996). Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer’s disease: possible relation to oxidative stress.
  15. (2005). Correlation between metal ions and clinical fi ndings in subjects affected by Alzheimer’s disease.
  16. (1999). Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.
  17. (1990). Detection of multiple forms of human ceruloplasmin. A novel Mr 200,000 form.
  18. (1985). Diagnosis of Alzheimer’s disease.
  19. (2003). Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice.
  20. (2006). Elevated cortical zinc in Alzheimer disease.
  21. (2002). Elevation of serum copper levels in Alzheimer’s disease.
  22. (2005). Excess of serum copper not related to ceruloplasmin in Alzheimer disease.
  23. (2000). In situ catalysis by neurofi brillary tangles and senile plaques in Alzheimer’s disease: a central role for bound transition metals.
  24. (2003). In vivo reduction of amyloid-beta by a mutant copper transporter.
  25. (1996). Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders.
  26. (1997). Iron accumulation in Alzheimer disease is a source of redox-generated free radicals.
  27. (1999). Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic.
  28. (2002). Malondialdehyde, superoxide dismutase, melatonin, iron, copper and zinc blood concentrations in patients with Alzheimer Disease: cross-sectional study.
  29. (2002). Metal complexing agents as therapies for Alzheimer’s disease.
  30. (2003). Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
  31. (1975). Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician.
  32. (1989). Sensitive, direct colorimetric assay for copper in serum.
  33. (2004). Serum copper: a biomarker for Alzheimer disease?
  34. (1999). Serum zinc, copper, insulin and lipids in Alzheimer’s disease epsilon 4 apolipoprotein E allele carriers.
  35. (2003). Structure of the Alzheimer’s disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis.
  36. (2002). Structure to function relationships in ceruloplasmin: a ‘moonlighting’ protein. Cell Mol.
  37. (1952). Studies on copper metabolism I. A method for the determination of copper in whole blood, red blood cells, and plasma.
  38. (1999). The Alzheimer’s disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures.
  39. (2003). Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer’s disease.
  40. (2004). Trace elements and cognitive impairment: an elderly cohort study.
  41. (1987). Trace elements in the human central nervous system studied with neutron activation analysis.
  42. (2005). Very low plasma copper levels do not automatically imply severe copper defi ciency.
  43. (1991). Wilson disease: clinical presentation, treatment, and survival.
  44. (2001). Wilson’s disease.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.